Literature DB >> 22778814

ACS chemical neuroscience molecule spotlight on Valdoxen.

Corey R Hopkins1.   

Abstract

A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT(2C) receptor.

Entities:  

Keywords:  MDD; NNDI; Valdoxen; major depressive disorders; norepinephrine-dopamine disinhibitor

Mesh：

Substances：

Year:  2010        PMID： 22778814      PMCID： PMC3368641          DOI： 10.1021/cn100062j

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN： 1948-7193            Impact factor:   4.418


  7 in total

Review 1.  Depression and antisocial personality disorder: two contrasting disorders of 5HT function.

Authors:  J F W Deakin
Journal:  J Neural Transm Suppl       Date:  2003

Review 2.  Risk factors and predictors of compliance in depression.

Authors:  Koen Demyttenaere
Journal:  Eur Neuropsychopharmacol       Date:  2003-09       Impact factor: 4.600

Review 3.  Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies.

Authors:  Pim Cuijpers; Annemieke van Straten; Patricia van Oppen; Gerhard Andersson
Journal:  J Clin Psychiatry       Date:  2008-08-12       Impact factor: 4.384

4.  Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.

Authors:  Jean Pierre Olié; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2007-05-04       Impact factor: 5.176

5.  Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine.

Authors:  Stuart A Montgomery; Siegfried Kasper
Journal:  Int Clin Psychopharmacol       Date:  2007-09       Impact factor: 1.659

6.  Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.

Authors:  S H Kennedy; R Emsley
Journal:  Eur Neuropsychopharmacol       Date:  2005-10-24       Impact factor: 4.600

7.  Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.

Authors:  H Lôo; A Hale; H D'haenen
Journal:  Int Clin Psychopharmacol       Date:  2002-09       Impact factor: 1.659
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.